CTIS2022-502534-23-00进行中（未招募）1 期
BEX17501
Sanofi-Aventis Research & Development0 个研究点目标入组 6 人开始时间: 2023年3月27日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by the body and to assess the extent to which SAR441566 becomes available to the body when given by mouthCTIS2023-508030-33-00Sanofi-Aventis Recherche & Developpement13
招募中
1 期
Dose escalation trial of BNT152+153 in patients with cancerVarious solid tumors that are metastatic or unresectableMedDRA version: 20.0Level: LLTClassification code: 10025648Term: Malignant mast cell tumors unspecified site extranodal and solid organ sites Class: 10029104CTIS2023-509508-13-00BioNTech SE4
进行中（未招募）
1 期
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease ParticipantsAlzheimer’s DiseaseMedDRA version: 20.0Level: LLTClassification code: 10001896Term: Alzheimer's disease Class: 10029205CTIS2024-514004-14-00ovartis Pharma AG25
进行中（未招募）
1 期
A Phase 1 Study Evaluating Relative Bioavailability of Sprinkled Ritlecitinib in Applesauce, Yoghurt, and Strawberry Jam and Evaluating the Effect of Food on the Bioavailability of Ritlecitinib Intact Blend-In Capsule in Healthy Adult Participants.Alopecia Areata, Rheumatoid Arthritis, Vitiligo, Ulcerative Colitis and Crohn's DiseaseMedDRA version: 21.1Level: PTClassification code: 10047642Term: Vitiligo Class: 100000004858MedDRA version: 21.0Level: PTClassification code: 10039073Term: Rheumatoid arthritis Class: 100000004859MedDRA version: 20.1Level: LLTClassification code: 10045365Term: Ulcerative colitis Class: 10017947MedDRA version: 20.0Level: PTClassification code: 10001761Term: Alopecia areata Class: 100000004858MedDRA version: 20.0Level: PTClassification code: 10011401Term: Crohn's disease Class: 100000004856CTIS2022-502872-22-00Pfizer Inc.12
进行中（未招募）
1 期
Safety and immune responses after vaccination with two investigational RNA-based vaccines against tuberculosis in healthy volunteersMedDRA version: 21.1Level: LLTClassification code: 10045023Term: Tuberculosis prophylaxis Class: 10042613MedDRA version: 21.1Level: PTClassification code: 10072084Term: Tuberculosis immunisation Class: 100000004865TuberculosisCTIS2023-509515-89-00BioNTech SE128